UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934

 

February 5, 2004
Date of Report (Date of earliest event reported)

 

WATSON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

0-20045

 

95-3872914

(State or other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification Number)

 

 

 

 

 

311 Bonnie Circle
Corona, California

 

 

 

92880

(Address of principal executive
offices)

 

 

 

(Zip Code)

 

(909) 493-5300
(Registrant’s telephone number, including area code)

 

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Item 7.    Financial Statements, Pro Forma Financial Information and Exhibits.

 

c.  Exhibits

 

99.1           News Release titled “Watson Pharmaceuticals Reports Earnings for Fourth Quarter 2003” dated February 5, 2004.

 

Item 12.  Results of Operations and Financial Condition.

 

On February 5, 2004, Watson Pharmaceuticals, Inc. (the Company) issued a news release announcing its financial results for the fourth quarter and full year ended December 31, 2003.  A copy of the Company’s news release is attached hereto as Exhibit 99.1.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:

February 5, 2004.

WATSON PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Charles P. Slacik

 

 

 

 

Charles P. Slacik

 

 

 

Executive Vice President and
Chief Financial Officer

 

3